 << Return to Faculty & Staff page
Ph.D.
Assistant Professor
Office Location:
Room 126C Charles T. Wethington Building
College of Health Sciences
900 S. Limestone
University of Kentucky
Lexington, Kentucky 40536-0200
Office Phone:
(859) 323-1100 Ext. 80849
Office Fax:
(859) 323-8957
Email:
oroakl1@uky.edu |
 |
Scholarly Interest:
Concurrent Infection with P.carinii and CMV in mice
Despite the practice of antimicrobial prophylaxis, CMV and P.
carinii (PC) pneumonia (PCP) are both leading cause of morbidity and
mortality in patients with immunocompromised states resulting from
malignancies, solid organ and bone marrow transplants, or AIDS. In
addition, newborns with congenital or perinatal CMV infection also
suffer from concomittent PCP. The interaction of these pathogens and
their effects on host immune response is not clearly understood.
Therefore, it is important to better understand the pathophysiology
of PC and CMV dual infection.
Mechanisms of Exacerbation of GVHD by Murine CMV in BMT
Bone marrow transplantation (BMT) is being used for the
treatment of a growing number of life threatening illnesses from
leukemia to aplastic anemia. While many lives have been saved, the
procedure is associated with serious risks, notably opportunistic
infections and the development of graft versus host disease (GVHD).
Cytomegalovirus (CMV) infection has been the most prevalent
infectious agent found in BMT patients, and, prior to the use of
preemptive ganciclovir therapy, was a major cause of death after BMT.
The highest risk scenario for CMV occurs when a sero-positive
recipient (with latent viral infection) receives bone marrow from a
sero-negative donor, thus transplanting a “CMV-naïve” immune system
into a host in whom the virus can reactivate during periods of
immunosuppression. It is now well recognized that CMV infection can
exacerbate GVHD after allogeneic BMT. However, the precise
mechanisms by which CMV worsens GVHD remain incompletely defined.
Re-activation of Murine Cytomegalovirus in BMT and its Impact
on Pneumonitis
Bone marrow transplantation (BMT) is being used extensively for the
treatment of numerous life threatening diseases from leukemia to
aplastic anemia. Whilst the procedure can offer life saving relief,
it is also associated with serious risks, most notably opportunistic
infections, including cytomegalovirus (CMV) graft-versus-host
disease (GVHD) and numerous pulmonary complications. Interstitial
pneumonia (IP) is the most common manifestation of CMV morbidity in
BMT patients despite adequate treatment. The precise mechanism by
which re-activating latent virus worsens IP is still unclear. My
research focus is to define the mechanisms by which prior CMV
infection causes exacerbation of IP in a murine model of allogeneic
BMT. |